Showing results (161-170 of 219) with videos related to
Sort By:
Pageof 22
Cell Metabolism|November 5, 2020
Functional Genomics Identifies Metabolic Vulnerabilities in Pancreatic CancerDouglas E Biancur, Kevin S Kapner, Keisuke Yamamoto, et al.Cancer Genomics & Proteomics|October 25, 2020
Deletion of Histone Methyltransferase G9a Suppresses Mutant Kras-driven Pancreatic CarcinogenesisHiroyuki Kato, Keisuke Tateishi, Hiroaki Fujiwara, et al.Gastrointestinal Endoscopy|October 20, 2009
Endoscopic evaluation of factors contributing to intrapancreatic biliary stricture in autoimmune pancreatitisKenji Hirano, Minoru Tada, Hiroyuki Isayama, et al.Journal of Cancer Research and Clinical Oncology|November 16, 2014
The inhibition of renin-angiotensin system in advanced pancreatic cancer: an exploratory analysis in 349 patientsYousuke Nakai, Hiroyuki Isayama, Takashi Sasaki, et al.Biochemical and Biophysical Research Communications|March 25, 2010
Gastric cancer cell line Hs746T harbors a splice site mutation of c-Met causing juxtamembrane domain deletionYoshinari Asaoka, Motohisa Tada, Tsuneo Ikenoue, et al.Digestive Endoscopy : Official Journal of the Japan Gastroenterological Endoscopy Society|April 18, 2012
Endoscopic removal of a spontaneously fractured biliary uncovered self-expandable metal stentKazumichi Kawakubo, Hiroyuki Isayama, Takeshi Tsujino, et al.Investigational New Drugs|July 8, 2010
Feasibility study of gemcitabine and cisplatin combination chemotherapy for patients with refractory biliary tract cancerTakashi Sasaki, Hiroyuki Isayama, Yousuke Nakai, et al.European Heart Journal Open|September 17, 2024
Basal inferoseptal segment is highly susceptible to deformation in the clinical spectrum of transthyretin-derived amyloid cardiomyopathyToshihiro Tsuruda, Hiroshi Nakada, Yoshimasa Yamamura, et al.Cancer Chemotherapy and Pharmacology|October 15, 2013
A retrospective analysis of early CA19‑9 change in salvage chemotherapy for refractory pancreatic cancerYousuke Nakai, Hiroyuki Isayama, Takashi Sasaki, et al.Cancer Chemotherapy and Pharmacology|August 22, 2014
A phase I trial of gemcitabine, S-1 and LV combination (GSL) therapy in advanced pancreatic cancerYousuke Nakai, Hiroyuki Isayama, Kei Saito, et al.Pageof 22